Holen Sie sich die Stockscreener-App
11.08
4.89%
-0.57
Handel nachbörslich:
11.08
Hutchmed China Limited Adr Aktie (HCM) Neueste Nachrichten
NMPA clears HUTCHMED (HCM) drug ORPATHYS for MET-amplified gastric cancer - Stock Titan
HUTCHMED Announces NMPA Approval for ORPATHYS® for the - GlobeNewswire
Price to book forward of HUTCHMED (China) Limited Sponsored ADR – LSE:0J7G - TradingView
HUTCHMED (NASDAQ: HCM) schedules 2026 half-year results and investor webcasts - Stock Titan
HUTCHMED to Announce 2026 Half-Year Financial Results - GlobeNewswire
HUTCHMED (HCM) details 2015 and 2026 share option blocklisting return - Stock Titan
REGHutchmed China LtdAnnouncement on blocklisting six monthly return - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LS:A2AF74) - TradingView
A2AF74 Forecast — Price Target — Prediction for 2027 - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (GETTEX:H7T1) - TradingView
H7T1 Forecast — Price Target — Prediction for 2027 - TradingView
0J7G Forecast — Price Target — Prediction for 2027 - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LSX:A2AF74) - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (NASDAQ:HCM) - TradingView
Pivotal fanregratinib ICC data and China NDA review for HUTCHMED (NASDAQ: HCM) - Stock Titan
RCSHutchmed China LtdHUTCHMED Highlights Phase II Data at ESMO - TradingView
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib - GlobeNewswire
HUTCHMED analyst targets stay high, shares trade well below consensus - AD HOC NEWS
HUTCHMED Announces Phase III China Data from ESLIM-02 Study of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia - aastocks.com
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress - GlobeNewswire Inc.
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in - GlobeNewswire
HUTCHMED (Nasdaq: HCM) files AIM block for 43,616,756 shares - Stock Titan
HCMHUTCHMED (China) Limited ADR Stock Price and Quote - Finviz
HUTCHMED (Nasdaq: HCM) showcases savolitinib, fruquintinib and surufatinib data at ASCO 2026 - Stock Titan
HUTCHMED: ELUNATE and TYVYT Combination Therapy Approved by NMPA for Advanced or Metastatic Renal Cell Carcinoma - AASTOCKS.com
HUTCHMED to Present Multiple Study Data at ASCO Annual Meeting in US - AASTOCKS.com
New HUTCHMED (HCM) ELUNATE plus TYVYT approval targets second-line kidney cancer - Stock Titan
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting - GlobeNewswire
HUTCHMED (HCM) shareholders back all AGM votes including 2026 option scheme - Stock Titan
HUTCHMED (NASDAQ:HCM) Hits New 52-Week LowWhat's Next? - MarketBeat
HUTCHMED To Present Data at American Association of Cancer Research Annual Meeting 2026 - AASTOCKS.com
HUTCHMED (Nasdaq: HCM) reports 872,335,120 voting shares - Stock Titan
和黃醫藥(00013.HK)索樂匹尼布上市申請獲受理並納入優先審評 - AASTOCKS.com
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
HUTCHMED (Nasdaq: HCM) gains China priority review and breakthrough status for sovleplenib - Stock Titan
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference - Yahoo Finance
HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026 - The Manila Times
Hutchmed China (NASDAQ:HCM) Gains Attention Amid Healthcare Momentum - Kalkine Media
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Rating of "Hold" by Analysts - MarketBeat
Revenue per share of HUTCHMED (China) Limited Sponsored ADR – FWB:H7T1 - TradingView — Track All Markets
HCM Stock Price, Quote & Chart | HUTCHMED CHINA-ADR (NASDAQ:HCM) - ChartMill
HUTCHMED (HCM) showcases ATTC and surufatinib study data at AACR 2026 - Stock Titan
HUTCHMED (HCM) plans 2026 AGM, 10% buyback mandate and 5% option pool - Stock Titan
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 - GlobeNewswire
HUTCHMED (LON:HCM) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance Singapore
Zai Lab Limited (ZLAB) stock price, news, quote and history - uk.finance.yahoo.com
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo Finance
Short Interest in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Decreases By 13.7% - MarketBeat
HUTCHMED (NASDAQ:HCM) Shares Gap UpTime to Buy? - MarketBeat
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
0.15%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):